

10/509675

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DT04 Rec'd PCT/PTO 08 OCT 2004

In re the Application of:

Piero DEL SOLDATO

Application No.: New Application

Filed: October 8, 2004

For: DRUGS FOR THE ARTHRITIS TREATMENT

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: 026220-00055

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

October 8, 2004


Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date or the date of filing a CPA, OR (b) before the mailing date of a first Office Action on the merits in the present application, or (c) accompanies a Request for Continued Examination. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

- ☐ c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$130.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

Respectfully submitted,


Richard U. Berman
Registration No. 39,107

Customer No. 004372
Arent Fox PLLC
1050 Connecticut Avenue, N.W., Suite 400
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810

RJB:mso

Enclosures: PTO-1449 Form; Search Report; References (13)

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

026220-00055

SERIAL NO.

10/509675
New Application

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Piero DEL SOLDATO

FILING DATE

October 8, 2004

GROUP

Unknown

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA	5,621,000	4/15/1997	Barbara ARENA, et al.			
	AB	5,861,426	1/19/1999	Piero DEL SOLDATO, et al.			
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO PART		
	AG	DE 44 20 523 A1	12/14/1995	Deutschland				XX	
	AH								
	AI								
	AJ								
	AK								
	AL								

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Piero DEL SOLDATO, et al.; "No-Aspirins: A Class of New Anti-Inflammatory and Antithrombotic Agents"; August 1999; Vol. 20, No. 8 Pages 319-323
	AN	L. CUZZOLIN, et al.; "Anti-Inflammatory Potency and Gastrointestinal Toxicity of A New Compound, Nitronaproxen"; August 26, 1994; Vol. 31, No.1, Pages 61-65
	AO	P. DEL SOLDATO, et al.; "Nitric-Oxide-Releasing NSAIDs, A Novel Class of Safe and Effective Anti-Inflammatory Agents; 1996; Vol. 4, No. 2, Pages 181-188

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. 026220-00055	SERIAL NO. 10/509675 New Application
	APPLICANT Piero DEL SOLDATO	
	FILING DATE October 8, 2004	GROUP Unknown

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO PART.		
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AM	Shinichi KATO, et al.; "Low Gastric Toxicity of Nitric Oxide-Releasing Aspirin, NCX-4016, in Rats with Cirrhosis and Arthritis"; August 2001; Vol. 46, No.8, Pages 1690-1699
	AN	Stefano FIORUCCI, et al.; "No-Releasing NSAIDs Modulate Cytokine Secretion"; 2001; Vol. 16, Pages 171-178
	AO	R J VAN'T HOF; "No-NSAIDs: A Novel Class of Osteoclast Inhibitors; May 7, 1999; Vol. 64 No. SUPPL 1, Page S59

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. 026220-00055	SERIAL NO. 10 1509675
	APPLICANT Piero DEL SOLDATO	
	FILING DATE October 8, 2004	GROUP Unknown

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
							YES	NO	PART.
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	J.L. BURGAUD, et al.; "Treatment of Septic Shock Treatment of Urinary Incontinence Treatment of Osteoporosis Nitric Oxide Donor"; 1999; Vol. 24, No. 8, Pages 858-861
	AN	Kenneth J. ARMOUR, et al.; "Inhibition of Bone Resorption in Vitro and Prevention of Ovariectomy-Induced Bone Loss In Vivo by Flurbiprofen Nitroxybutylester (HCT1026); September 2001; Vol. 44, No. 9, Pages 2185-2192
	AO	Mark J. PAUL-CLARK, et al. "Potent Antiarthritic Properties of a Glucocorticoid derivative, NCX-1015, in an Experimental Model of Arthritis"; February 5, 2002; Vol. 99, No. 3, Pages 1677-1682

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 026220-00055	SERIAL NO. 107509675 New Application
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Piero DEL SOLDATO	
		FILING DATE October 8, 2004	GROUP Unknown

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO PART.		
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	J.L. BURGAUD, et al. "Nitric-Oxide Releasing Molecules: A New Class of Drugs with Several Major Indications" ; 2002; Vol. 8, No. 3, Pages 201-213
	AN	
	AO	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	